3SBio (STU:83B) Total Receivables: €168 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:83B 3SBio Inc STU:83B
87 GF Score
Price €1.88
GF Value €1.40
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is 3SBio Total Receivables?

3SBio STU:83B -2.62% 87 Total Receivables is €168 Mil as of Dec. 2025. GuruFocus rates STU:83B with a GF Score™ of 87/100 and a GF Value™ of €1.40 (Significantly Overvalued). The stock has 1 warning sign investors should review.

3SBio's Total Receivables for the quarter that ended in Dec. 2025 was €168 Mil.

3SBio Total Receivables Historical Data

* Premium members only.

The historical data trend for 3SBio's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

3SBio Total Receivables Chart

3SBio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 219.47 245.98 286.09 224.72 168.47

3SBio Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 286.09 309.61 224.72 281.34 168.47
STU:83B
87GF Score
3SBio Inc STU:83B
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

3SBio Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of €168 Mil mean?
3SBio (STU:83B) has a Total Receivables of €168 Mil as of Dec. 2025. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on 3SBio and its competitors.
Is 3SBio's Total Receivables too high?
3SBio's current Total Receivables is €168 Mil. Overall, 3SBio has a GF Score™ of 87/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does 3SBio's Total Receivables compare to VRTX and REGN?
3SBio's Total Receivables of €168 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on 3SBio and its competitors. 3SBio's current Total Receivables is €168 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 3SBio stock overvalued right now?
Based on GuruFocus' analysis, 3SBio (STU:83B) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.40, compared to a current price of €1.88 — trading 34% above its estimated fair value. The current Total Receivables is €168 Mil. 3SBio's overall GF Score™ is 87/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For 3SBio (STU:83B), the current Total Receivables is €168 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is 3SBio (STU:83B) Overvalued in 2026?

Based on GuruFocus' analysis, 3SBio stock appears to be overvalued. The current stock price of €1.88 is trading 34% above its estimated GF Value™ of €1.40. GuruFocus considers 3SBio to be Significantly Overvalued.

Key valuation signals for STU:83B:

  • Total Receivables: €168 Mil
  • GF Value™: €1.40 vs. price of €1.88 (34% above fair value)
  • GF Score™: 87/100 with 1 warning sign

No single metric tells the full story. See the STU:83B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

3SBio Business Description

Other Exchanges TRSBF:USA01530:Hong Kong
Address No. 3 A1, Road 10, Shenyang Economy and Technology Development Zone, Shenyang, CHN
3SBio Inc is an investment holding company. It is a primary biotechnology company. The company is principally engaged in the development, production, marketing and sale of biopharmaceutical products in the People's Republic of China. The group has only one operating segment. It has presence in Chinese mainland, USA, Other countries/regions. The majority of revenue comes from USA. The core commercialized products of the group include several bio-pharmaceutical drugs, namely, TPIAO, recombinant human erythropoietin (rhEPO) products EPIAO and SEPO, Yisaipu and Cipterbin, and a small molecule drug, Mandi series of minoxidil drugs.
87GF Score

Get the complete analysis for STU:83B

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.88
Price
€1.40
GF Value